Unresectable Stage Iii Non Small Cell Lung Cancer clinical trials

Explore recruiting unresectable stage iii non small cell lung cancer clinical trials.

Recruiting unresectable stage iii non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Unresectable Stage Iii Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Single-Arm Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Platinum-Based Concurrent Chemoradiation

Slovenia, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)

Poland, Spain, Portugal, Belgium, France, Greece +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer

Spain, Norway, Sweden, Poland, France, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequential hyPOfractionated chemoRADiotherapy in unfit or elderly patients with unresectable stage III non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer

Netherlands, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

France, Ireland, Germany, Greece, Bulgaria, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Unresectable Stage Iii Non Small Cell Lung Cancer trials by city

Unresectable Stage Iii Non Small Cell Lung Cancer in Toronto Unresectable Stage Iii Non Small Cell Lung Cancer in Vancouver Unresectable Stage Iii Non Small Cell Lung Cancer in Montreal Unresectable Stage Iii Non Small Cell Lung Cancer in Calgary Unresectable Stage Iii Non Small Cell Lung Cancer in Edmonton Unresectable Stage Iii Non Small Cell Lung Cancer in Ottawa Unresectable Stage Iii Non Small Cell Lung Cancer in Winnipeg Unresectable Stage Iii Non Small Cell Lung Cancer in Quebec City Unresectable Stage Iii Non Small Cell Lung Cancer in Hamilton Unresectable Stage Iii Non Small Cell Lung Cancer in Kitchener Unresectable Stage Iii Non Small Cell Lung Cancer in London Unresectable Stage Iii Non Small Cell Lung Cancer in Halifax Unresectable Stage Iii Non Small Cell Lung Cancer in New York Unresectable Stage Iii Non Small Cell Lung Cancer in Los Angeles Unresectable Stage Iii Non Small Cell Lung Cancer in Chicago Unresectable Stage Iii Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease